Novo Nordisk snags high-dose Ozempic approval, turning up the heat on Lilly’s Trulicity
Novo Nordisk’s Ozempic, grappling with Eli Lilly’s Trulicity for supremacy of the GLP-1 diabetes market, hit a snag last year when the FDA refused to review a new dos...